https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Comparing Explainable Machine Learning Approaches With Traditional Statistical Methods for Evaluating Stroke Risk Models: Retrospective Cohort Study. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52405 Wed 28 Feb 2024 15:54:25 AEDT ]]> Comparative efficacy and safety of pharmacologic interventions to prevent mother-to-child transmission of hepatitis B virus: a systematic review and network meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51837 Wed 20 Sep 2023 16:11:23 AEST ]]> Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48928 Wed 19 Apr 2023 15:08:55 AEST ]]> Evaluation of transitions from early hypertension to hypertensive chronic kidney disease, coronary artery disease, stroke and mortality: a Thai real-world data cohort https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52406 Wed 11 Oct 2023 11:51:59 AEDT ]]> Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51602 Tue 12 Sep 2023 13:35:14 AEST ]]> An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50654 Tue 01 Aug 2023 12:10:37 AEST ]]> Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52121 Thu 28 Sep 2023 15:03:25 AEST ]]> Development of risk prediction models for severe periodontitis in a Thai population: statistical and machine learning approaches https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53976 Thu 25 Jan 2024 10:37:08 AEDT ]]> Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48407 Thu 16 Mar 2023 14:03:45 AEDT ]]> Systematic review of natural language processing for recurrent cancer detection from electronic medical records https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54276 Thu 15 Feb 2024 14:38:33 AEDT ]]> Delayed versus primary closure to minimize risk of surgical-site infection for complicated appendicitis: A secondary analysis of a randomized trial using counterfactual prediction modeling https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55043 Thu 04 Apr 2024 13:51:40 AEDT ]]> External validation of prognostic models for chronic kidney disease among type 2 diabetes https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47330 Thu 02 May 2024 15:45:08 AEST ]]> Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13258 Sat 24 Mar 2018 08:15:59 AEDT ]]> Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18169 Sat 24 Mar 2018 08:04:35 AEDT ]]> The association between complement component 2/complement factor B polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20368 Sat 24 Mar 2018 07:58:11 AEDT ]]> Prevention of venous thromboembolism in gynecological cancer patients undergoing major abdominopelvic surgery: a systematic review and network meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46176 Mon 14 Nov 2022 08:57:36 AEDT ]]> Development and external validation of automated ICD-10 coding from discharge summaries using deep learning approaches https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51955 Fri 22 Sep 2023 17:07:15 AEST ]]> Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52946 Fri 03 Nov 2023 10:58:12 AEDT ]]> Causal associations of urate with cardiovascular risk factors: two-sample Mendelian Randomization https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42787 ABCG2, SLC2A9, SLC17A1, SLC22A11, and SLC22A12 showed consistent causal effects of urate on HDL-C from all methods with 0.038 to 0.057 SD decrease in HDL-C per 1 mg/dl increase of urate, and no evidence of horizontal pleiotropy was detected. Conclusion: Our study suggests a significant and robust causal effect of genetically predicted urate on HDL-C. This finding may explain a small proportion (7%) of the association between increased urate and cardiovascular disease but points to urate being a novel cardiac risk factor.]]> Fri 02 Sep 2022 14:02:17 AEST ]]> Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53516 Fri 01 Dec 2023 11:06:04 AEDT ]]> Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31991 1 year (RAAS2). An augmented inverse-probability weighting (AIPW) method was used to estimate potential-outcome mean (POM) and average treatment-effect (ATE). Multi-logit and Poisson regressions were used for treatment and outcome models, respectively. Analyses were stratified by ESRD, death before/after ESRD for diabetic and non-diabetic groups. STATA 14.0 was used for statistical analyses. Results: Among 15,032 diabetic patients, 2346 (15.6%), 2351 (18.5%), and 1607 (68.5%) developed ESRD, died before ESRD, and died after ESRD, respectively. Only RAAS2 effect was significant on ESRD, death before and after ESRD. The ESRD rates were 12.9%, versus 20.0% for RAAS2 and non-RAAS, respectively, resulted in significant risk differences (RD) of -7.2% (95% CI: -8.8%, -5.5%), and a numbers needed-to-treat (NNT) of 14. Death rates before ESRD for these corresponding groups were 14.4% (12.9%, 15.9%) and 19.6% (18.7%, 20.4%) with a NNT of 19. Death rates after ESRD in RAAS2 was lower than non-RASS group (i.e., 62.8% (55.5%, 68.9%) versus 68.1% (65.9%, 70.4%)) but this was not significant. RAAS2 effects on ESRD and death before ESRD were persistently significant in non-diabetic patients (n = 17,074) but not for death after ESRD with the NNT of about 15 and 16 respectively. Conclusions: Receiving RAAS blockade for 1 year or longer could prevent both CKD progression to ESRD and premature mortality.]]> Fri 01 Apr 2022 09:26:45 AEDT ]]>